866-997-4948(US-Canada Toll Free)

Renal Cell Carcinoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 256 Pages


Global Markets Directs, \'Renal Cell Carcinoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. Renal Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
  • A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Renal Cell Carcinoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Renal Cell Carcinoma 11
Renal Cell Carcinoma Therapeutics under Development by Companies 13
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Renal Cell Carcinoma Therapeutics - Products under Development by Companies 22
Renal Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 26
Companies Involved in Renal Cell Carcinoma Therapeutics Development 27
Bristol-Myers Squibb Company 27
Boehringer Ingelheim GmbH 28
Kyowa Hakko Kirin Co., Ltd. 29
Amgen Inc. 30
AstraZeneca PLC 31
GlaxoSmithKline plc 32
Seattle Genetics, Inc. 33
Genentech, Inc. 34
Antigenics, Inc. 35
MedImmune LLC 36
Celltrion, Inc. 37
Novartis AG 38
Astellas Pharma Inc. 39
Ono Pharmaceutical Co., Ltd. 40
Pfizer Inc. 41
Taiho Pharmaceutical Co., Ltd. 42
Bayer AG 43
Hemispherx Biopharma, Inc. 44
Celldex Therapeutics, Inc. 45
Active Biotech AB 46
Lorus Therapeutics Inc 47
Lpath, Inc. 48
Bionomics Limited 49
Flamel Technologies S.A. 50
Antisoma plc 51
MOLOGEN AG 52
Jiangsu Hengrui Medicine Co., Ltd. 53
Threshold Pharmaceuticals, Inc. 54
Rexahn Pharmaceuticals, Inc. 55
Colby Pharmaceutical Company 56
Wilex AG 57
Glycotope GmbH 58
immatics biotechnologies GmbH 59
Curacyte AG 60
Argos Therapeutics, Inc. 61
MacroGenics, Inc. 62
Five Prime Therapeutics, Inc. 63
Jennerex Biotherapeutics, Inc. 64
Advenchen Laboratories, LLC 65
Vaccinogen, Inc. 66
Immunocore Limited. 67
Tigris Pharmaceuticals, Inc. 68
TRACON Pharmaceuticals, Inc. 69
KAHR medical Ltd. 70
Anaphore, Inc. 71
n.v. BRUCELLS s.a. 72
Medical Enzymes AG 73
Incuron 74
FCB-Pharmicell Co.,Ltd. 75
BiOrion Technologies B.V. 76
Ampio Pharmaceuticals, Inc. 77
Renal Cell Carcinoma - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 85
rilotumumab - Drug Profile 85
regorafenib - Drug Profile 87
sorafenib tosylate - Drug Profile 89
axitinib - Drug Profile 93
sunitinib malate - Drug Profile 96
RG-7422 - Drug Profile 100
cediranib maleate - Drug Profile 102
linifanib - Drug Profile 105
MDX-1203 - Drug Profile 107
R-100 - Drug Profile 108
tasquinimod - Drug Profile 110
LOR-1284 - Drug Profile 112
MKC-1106-PP - Drug Profile 113
Asonep - Drug Profile 115
IMA-901 - Drug Profile 117
FP-1039 - Drug Profile 119
pexastimogene devacirepvec - Drug Profile 121
CDX-014 - Drug Profile 123
CBL-0137 - Drug Profile 124
AGS-003 - Drug Profile 125
nintedanib - Drug Profile 127
GlutaDON - Drug Profile 129
tivozanib - Drug Profile 131
CST-101 - Drug Profile 134
GFB-204 - Drug Profile 135
AS-1409 - Drug Profile 136
girentuximab - Drug Profile 138
Hemoximer - Drug Profile 140
KAHR-101 - Drug Profile 142
BNC-105 - Drug Profile 143
TRC-105 - Drug Profile 145
MDX-1411 - Drug Profile 147
nivolumab - Drug Profile 148
nelfinavir mesylate + [temsirolimus] - Drug Profile 151
AGS-16M8F - Drug Profile 152
hydroxychloroquine - Drug Profile 153
pazopanib hydrochloride - Drug Profile 154
pazopanib hydrochloride - Drug Profile 158
MGA-271 - Drug Profile 162
DC-AdGM-CAIX - Drug Profile 163
(tegafur + gimeracil + oteracil potassium) - Drug Profile 164
X-82 - Drug Profile 167
BCL-004 - Drug Profile 168
Famitinib - Drug Profile 169
RYI-008 - Drug Profile 171
ImmTAC Targeting MAGE-A3 HLA-A1 - Drug Profile 172
ImmTAC Targeting MAGE A3 - Drug Profile 173
AL-8326 - Drug Profile 174
AMG-172 - Drug Profile 175
Mobilan - Drug Profile 177
NCE-001 - Drug Profile 178
AGS-16C3F - Drug Profile 179
MEDI-4736 - Drug Profile 180
Drugs For Renal Cell Carcinoma - Drug Profile 181
BC-2059 - Drug Profile 182
BOT-191 - Drug Profile 183
XB-2202 - Drug Profile 184
OMRCA-01 - Drug Profile 185
KPT-251 - Drug Profile 187
Anti-CD70 Monoclonal Antibody-Drug Conjugate - Drug Profile 188
Immunotherapy For Renal Cancer - Drug Profile 189
Renal Cell Carcinoma Therapeutics - Drug Profile Updates 190
Renal Cell Carcinoma Therapeutics - Discontinued Products 239
Renal Cell Carcinoma Therapeutics - Dormant Products 240
Renal Cell Carcinoma - Product Development Milestones 243
Featured News & Press Releases 243

Appendix 251
Methodology 251
Coverage 251
Secondary Research 251
Primary Research 251
Expert Panel Validation 251
Contact Us 252
Disclaimer 252

List of Table


Number of Products Under Development for Renal Cell Carcinoma, H2 2013 15
Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2013 16
Number of Products under Development by Companies, H2 2013 18
Number of Products under Development by Companies, H2 2013 (Contd..1) 19
Number of Products under Development by Companies, H2 2013 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2013 21
Comparative Analysis by Late Stage Development, H2 2013 22
Comparative Analysis by Mid Clinical Stage Development, H2 2013 23
Comparative Analysis by Early Clinical Stage Development, H2 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 25
Products under Development by Companies, H2 2013 26
Products under Development by Companies, H2 2013 (Contd..1) 27
Products under Development by Companies, H2 2013 (Contd..2) 28
Products under Development by Companies, H2 2013 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2013 30
Bristol-Myers Squibb Company, H2 2013 31
Boehringer Ingelheim GmbH, H2 2013 32
Kyowa Hakko Kirin Co., Ltd., H2 2013 33
Amgen Inc., H2 2013 34
AstraZeneca PLC, H2 2013 35
GlaxoSmithKline plc, H2 2013 36
Seattle Genetics, Inc., H2 2013 37
Genentech, Inc., H2 2013 38
Antigenics, Inc., H2 2013 39
MedImmune LLC, H2 2013 40
Celltrion, Inc., H2 2013 41
Novartis AG, H2 2013 42
Astellas Pharma Inc., H2 2013 43
Ono Pharmaceutical Co., Ltd., H2 2013 44
Pfizer Inc., H2 2013 45
Taiho Pharmaceutical Co., Ltd., H2 2013 46
Bayer AG, H2 2013 47
Hemispherx Biopharma, Inc., H2 2013 48
Celldex Therapeutics, Inc., H2 2013 49
Active Biotech AB, H2 2013 50
Lorus Therapeutics Inc, H2 2013 51
Lpath, Inc., H2 2013 52
Bionomics Limited, H2 2013 53
Flamel Technologies S.A., H2 2013 54
Antisoma plc, H2 2013 55
MOLOGEN AG, H2 2013 56
Jiangsu Hengrui Medicine Co., Ltd., H2 2013 57
Threshold Pharmaceuticals, Inc., H2 2013 58
Rexahn Pharmaceuticals, Inc., H2 2013 59
Colby Pharmaceutical Company, H2 2013 60
Wilex AG, H2 2013 61
Glycotope GmbH, H2 2013 62
immatics biotechnologies GmbH, H2 2013 63
Curacyte AG, H2 2013 64
Argos Therapeutics, Inc., H2 2013 65
MacroGenics, Inc., H2 2013 66
Five Prime Therapeutics, Inc., H2 2013 67
Jennerex Biotherapeutics, Inc., H2 2013 68
Advenchen Laboratories, LLC, H2 2013 69
Vaccinogen, Inc., H2 2013 70
Immunocore Limited., H2 2013 71
Tigris Pharmaceuticals, Inc., H2 2013 72
TRACON Pharmaceuticals, Inc., H2 2013 73
KAHR medical Ltd., H2 2013 74
Anaphore, Inc., H2 2013 75
n.v. BRUCELLS s.a., H2 2013 76
Medical Enzymes AG, H2 2013 77
Incuron, H2 2013 78
FCB-Pharmicell Co.,Ltd., H2 2013 79
BiOrion Technologies B.V., H2 2013 80
Ampio Pharmaceuticals, Inc., H2 2013 81
Assessment by Monotherapy Products, H2 2013 82
Assessment by Combination Products, H2 2013 83
Assessment by Stage and Route of Administration, H2 2013 85
Assessment by Stage and Molecule Type, H2 2013 88
Renal Cell Carcinoma Therapeutics - Drug Profile Updates 194
Renal Cell Carcinoma Therapeutics - Discontinued Products 243
Renal Cell Carcinoma Therapeutics - Dormant Products 244
Renal Cell Carcinoma Therapeutics - Dormant Products (Contd..1) 245
Renal Cell Carcinoma Therapeutics - Dormant Products (Contd..3) 246

List of Chart


Number of Products under Development for Renal Cell Carcinoma, H2 2013 15
Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 21
Late Stage Products, H2 2013 22
Mid Clinical Stage Products, H2 2013 23
Early Clinical Stage Products, H2 2013 24
Discovery and Pre-Clinical Stage Products, H2 2013 25
Assessment by Monotherapy Products, H2 2013 82
Assessment by Combination Products, H2 2013 83
Assessment by Route of Administration, H2 2013 84
Assessment by Stage and Route of Administration, H2 2013 85
Assessment by Molecule Type, H2 2013 86
Assessment by Stage and Molecule Type, H2 2013 87

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *